Cancer cells may adapt to MYC-targeted therapies, particularly in HR-deficient backgrounds, by engaging compensatory DNA repair pathways, activating alternative transcriptional programs, or modulating checkpoint responses, potentially reducing the efficacy of MYC–DDR combinations. Here, MYC is linked to cancer.